Professor Carl Goodyear studied molecular biology at the University of Glasgow and graduated with honours. He then gained a PhD in molecular immunology. Upon completing his PhD, he moved to the US and worked in the Department of Medicine at the University of California at San Diego where he eventually held the position of Assistant Professor. During this period, he was awarded a Cancer Research Institute Postdoctoral Fellowship, became a National Blood Foundation Scholar, and received several awards including the National Blood Foundation David B. Pall Prize for Innovative Research in Transfusion Medicine and an Arthritis Foundation Investigator Award. In 2006 he was awarded a prestigious Arthritis Research UK Fellowship and returned to work in the UK at the Institute of Infection Immunity and Inflammation in the University of Glasgow. His research is currently focused on understanding immunopathogenesis of disease (i.e., Rheumatoid Arthritis & Osteoarthritis) and translating this knowledge into viable therapeutic agents for patients. He leads a Translational Immunology programme that provides the critical interface between clinical and basic science, with a specific focus on precision medicine. In parallel, he is also the Director of the GLAZgo Discovery Centre, a collaboration between the University of Glasgow and AstraZeneca to drive innovative academic/industry research. Professor Goodyear has published widely in the areas of immunobiology and rheumatology. He was elected a fellow of the Royal Society of Biology in 2016 and is a Visiting Research Fellow at the University of Birmingham, University of Newcastle and Visiting Professor at the University of the West of Scotland.